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MalnutritionNeedless to say, drug-eluting stents (DESs) signiﬁcantly reduce
the risk of restenosis after percutaneous coronary intervention
(PCI). However, effects of DES implantation have been limited in
patients on maintenance hemodialysis (HD) [1,2].
Basically, patients with renal impairment, particularly end-
stage renal disease, frequently have systemic atherosclerosis [3].
One possibility is that higher rates of prevalence of traditional risk
factors, such as advanced age, diabetes, and hypertension in the HD
population may affect such high cardiovascular events [3].
In this issue of the Journal of Cardiology, Nagata et al. [4] report
that low-density lipoprotein (LDL) cholesterol levels could not
predict major adverse cardiac events in HD patients undergoing
PCI. It is well known that lipid proﬁles greatly affect clinical
outcome in non-HD populations [5]. Moreover, many studies have
shown beneﬁcial effects of statins on the improvement of clinical
outcome data in non-HD patients undergoing coronary revascu-
larization. However, in HD patients, there are limited studies to
show the beneﬁcial effects of statins on the improvement of the
clinical outcome. For instance, 4D (Die Deutsche Diabetes Dialyze)
study did not prove that statins do not affect clinical outcome in
HD patients [6]. Therefore, whether statin use has a beneﬁcial
effect on clinical outcomes in the HD population has been
controversial and the debate is ongoing regarding the ideal LDL
cholesterol level. From these points, the ﬁndings of the article by
Nagata et al. [4] are concurring with the previous reports.
A recent post hoc analysis of the 4D study revealed that treatment
with atorvastatin signiﬁcantly reduces cardiac events in HD
patients with type 2 diabetes, if they have pretreatment LDL levels
>145 mg/dl [7]. Because of the limited number of enrolled patients
in the study by Nagata et al. [4], further studies should be warranted.
Also, the importance of HDL levels should also be investigated.
Protein-energy wasting (PEW), commonly observed in patients
with end-stage renal disease, is associated with increasing risk of
cardiovascular morbidity and mortality [8]. The PEW is alsoDOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.03.016
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inadequate nutritional intake. These associations are malnutrition,
inﬂammation, and atherosclerosis syndrome [9]. Inﬂammatory
processes are related to atherosclerosis progression, resulting in
worse clinical outcomes in the HD population [10]. From this point
of view, a simple method to clarify the risk stratiﬁcation for
cardiovascular mortality is attractive. Recently, the geriatric
nutritional risk index (GNRI) has been reported as a new screening
tool for PEW [11]. In assessing GNRI, serum albumin levels and
body mass index are important factors [12]. Nagata et al. [4] also
suggested that body mass index independently predicted the
incidence of major adverse cardiac events.
Epicardial coronary artery stenosis has a clinical impact on HD
patients. In addition, coronary microcirculatory impairment has
been an important issue in HD patients [13]. In such situations,
speciﬁc medical treatment such as nicorandil may have beneﬁcial
effects on improving coronary microcirculatory ﬂow, resulting in
better clinical prognosis in the HD population [14].
As described above, the manifestation and etiology of
cardiovascular disease between non-HD and HD subjects are
quite different. Also, unfortunately, evidence-based medical
therapies to improve clinical outcomes in HD patients have been
limited. Taken together, we should provide optimal strategies for
cardiovascular prevention, diagnosis, and decision-making in
patients on HD to improve their clinical outcomes. However,
before that, we have to know the characteristics precisely.
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